In Vitro Combination of Voriconazole and Miltefosine against Clinically Relevant Molds - Université Pierre et Marie Curie
Article Dans Une Revue Antimicrobial Agents and Chemotherapy Année : 2014

In Vitro Combination of Voriconazole and Miltefosine against Clinically Relevant Molds

Résumé

Invasive infections caused by filamentous fungi are a major threat for immunocompromised patients. Innate/acquired resistance to antifungal drugs might necessitate combination therapies. We assessed the potential combination of voriconazole with miltefosine, an original drug with antifungal activity against 33 clinically relevant mold isolates, including both azole-susceptible and -resistant Aspergillus . Using complete inhibition as an endpoint, interactions were indifferent for 32/33 isolates. An alternative 50% inhibition endpoint showed synergistic interactions for 14/33 isolates. Antagonism was absent.
Fichier principal
Vignette du fichier
imbert-et-al-2014-in-vitro-combination-of-voriconazole-and-miltefosine-against-clinically-relevant-molds.pdf (96.19 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04014164 , version 1 (04-09-2024)

Identifiants

Citer

S. Imbert, M. Palous, I. Meyer, E. Dannaoui, D. Mazier, et al.. In Vitro Combination of Voriconazole and Miltefosine against Clinically Relevant Molds. Antimicrobial Agents and Chemotherapy, 2014, 58 (11), pp.6996-6998. ⟨10.1128/AAC.03212-14⟩. ⟨hal-04014164⟩
36 Consultations
4 Téléchargements

Altmetric

Partager

More